Author

R. J. Daly

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 6 Assay:proteomics· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell signaling & trafficking· 3 Research Focus:drug response / drug discovery· 2 Approach:biophysical modeling· 1

Frequent Co-Authors

X. Ma· 3 shared E. V. Nguyen· 2 shared J. Hou· 2 shared M. J. Roy· 2 shared O. Patel· 2 shared S. Budnar· 2 shared T. R. Cotton· 2 shared A. Avila· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

X. Ma

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancer

X. Yang, X. Ma, T. Zhao, D. R. Croucher, E. V. Nguyen, K. C. Clark, C. Hu, S. L. Latham, C. Bayly-Jones, V. C. B. Nguyen, S. Budnar, S. Shin, L. K. Nguyen, T. R. Cotton, A. C. Chueh, , R. J. Daly

This study identifies a novel feed-forward signalling axis between PEAK1 and CAMK2 in TNBC, showing that targeting CAMK2 can inhibit PEAK1-driven oncogenic processes.

bioRxiv · Feb 14, 2024Cancer Biology

Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas

A. M. Fordham, L. M. Brown, C. Mayoh, A. Salib, Z. A. Barger, M. Wong, T. C. C. L. K. Sian, J. Xie, K. Gunther, P. Trebilcock, R. L. Terry, P. Barahona, P. Ajuyah, A. Sherstyuk, A. Avila, , E. D. Fleuren

The paper identifies FGFR aberrations as actionable targets in pediatric and AYA sarcomas using multi-platform profiling and shows FGFR inhibitors can inhibit tumor growth in PDX models.

bioRxiv · Jul 19, 2023 · PreprintCancer Biology

When two is a crowd - Structural mapping of PEAK pseudokinase interactions identifies 14 3 3 as a molecular switch for PEAK3/Crk signaling.

M. J. Roy, M. G. Surudoi, A. Kropp, J. Hou, W. Dai, J. M. Hardy, L.-Y. Liang, T. R. Cotton, B. C. Lechenberg, T. A. Dite, X. Ma, R. J. Daly, O. Patel, I. Lucet

The paper identifies 14-3-3 as a molecular switch for PEAK3/Crk signaling by mapping PEAK pseudokinase interactions and demonstrating a conserved high affinity 14-3-3 motif.

bioRxiv · Sep 1, 2022 · PreprintBiochemistry

PEAK3 pseudokinase represents a pro-migratory and -invasive signalling scaffold

J. Hou, E. V. Nguyen, M. Surudoi, M. J. Roy, O. Patel, I. S. Lucet, X. Ma, R. J. Daly

This study identifies PEAK3 as a pseudokinase that promotes cell migration and invasion through scaffolding interactions and tyrosine phosphorylation.

bioRxiv · Feb 17, 2021 · PreprintCancer Biology

Snail induces epithelial cell extrusion through transcriptional control of RhoA contractile signalling and cell matrix adhesion

K. Wee, S. Zadeh, S. Verma, R. J. Daly, A. S. Yap, M. J. Davis, S. Budnar

This study shows Snail induces cell extrusion through RhoA contractile signaling and reduced basal adhesion, independent of EMT.

bioRxiv · Apr 29, 2019 · PreprintCell Biology

MicroRNAs as potential therapeutics to enhance chemosensitivity in advancedprostate cancer

H.-M. Lin, I. Nikolic, J. Yang, L. Castillo, N. Deng, C.-L. Chan, N. K. Yeung, E. Dodson, B. Elsworth, C. Spielman, B. Lee, Z. Boyer, K. Simpson, R. J. Daly, L. G. Horvath, A. Swarbrick

This study identifies microRNA mimics that enhance taxane-induced apoptosis in CRPC cell lines, suggesting potential therapeutic use to improve chemosensitivity.

bioRxiv · Feb 28, 2018Cancer Biology